Nifedipine versus fosinopril in uninephrectomized diabetic rats. Antihypertensive agents have been shown to exert inequivalent effects on glomerular injury in experimental renal disease models. To compare the consequences of dissimilar antihypertensive regimens on the development of diabetic glomerulopathy, studies were performed in three groups of uninephrectomized moderately hyperglycemic diabetic rats. One group (DM) received no therapy except insulin. The remaining groups received insulin and either the angiotensin I converting enzyme inhibitor, fosinopril (FOS), or the calcium channel blocker, nifedipine (NIF). Both drugs lowered blood pressure comparably. At four to eight weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (QA) and the glomerular capillary hydraulic pressure (P0). Neither NIF nor FOS affected values for SNGFR or QA.
However, while FOS lowered GC and increased Kf, NIF did not affect these parameters. In longer term (8 month) studies, DM rats exhibited progressive albuminuria and glomerular sclerosis. FOS markedly limited development of albuminuria and glomerular injury, but NIF was ineffective in limiting either parameter of glomerular injury. Thus, in contrast to the beneficial effects of converting enzyme inhibitors, chronic calcium channel blockade with nifedipine fails to limit P0c or glomerular injury in diabetic rats. These findings lend further support to the concept that different classes of antihypertensive agents are not equally effective in protecting against diabetic glomerulopathy.
Systemic hypertension is an important risk factor for the progression of diabetic glomerulopathy [1] , and effective control of systemic blood pressure may slow the loss of renal function [2] . However, recent experimental and clinical observations suggest that all antihypertensive regimens may not prove equally successful in retarding glomerular injury. Studies in animal models of diabetes have indicated that angiotensin I converting enzyme inhibitor (CEI) therapy is extremely effective in preventing the development of albumiriuria and glomerular injury [3] [4] [5] , while other antihypertensive regimens such as combination vasodilator/diuretic therapy [4] or the calcium channel blocker, verapamil [5] , may be less successful. Clinical studies have suggested that antihypertensive classes may differ in their ability to reduce albuminuria in diabetic patients [6] [7] [8] [9] [10] , perhaps suggesting differential effects on intraglomerular hemodynamics. In this study, we sought to examine the hemodynamic and structural consequences of antihypertensive therapy © 1992 by the International Society of Nephrology with the calcium antagonist nifedipine in a rat model of diabetes, and to compare them with those of CEI.
Methods
Three groups of adult male Munich-Wistar rats, with initial weights of 280 to 300 g, were studied. All rats were initially subjected to removal of the right kidney under Brevital anesthesia (50 mg/kg i.p.), and two weeks later were made diabetic by intravenous tail injection of streptozotocin (STZ, Sigma Chemical Co., St. Louis, Missouri, USA), 60 mg/kg body weight. This combined approach was chosen to hasten the development of diabetic glomerulopathy, so that extensive damage could be expected in untreated rats in a time period about half that required in diabetes alone. Two days later, the diabetic state was confirmed by measurement of tail blood glucose (BG) level using a reflectance meter (Miles Ames Div., Miles Laboratories, Inc., Elkhart, Indiana, USA). Diabetic rats received daily evening injections of ultralente insulin (Iletin I, Eli Lilly & Co., Indianapolis, Indiana, USA), in doses individually adjusted to maintain BG levels between 200 and 400 mg/dl. BG levels were monitored at least once a week. All rats were fed standard rat chow (Rodent Laboratory Chow 5001, Ralston Purina Co., Richmond, Indiana, USA) ad libitum.
One diabetic group (DM) received no therapy other than insulin. A second group (DM/FOS) was treated with insulin and with the CEI fosinopril (E.R. Squibb & Sons, Inc., Princeton, New Jersey, USA), administered in the drinking water at a concentration of 200 mg/liter. The third group (DM/NIF) received the calcium antagonist nifedipine (NIF) (Pfizer Laboratories, New York, New York, USA), administered at a dose of 5 mg s.c. b.i.d. This route of administration was chosen after pilot studies indicated inability to reduce systemic blood pressure when nifedipine was supplied in the food. Doses of all antihypertensive regimens were adjusted as needed to maintain the systolic blood pressure in the range of 100 to 120 mm Hg, representing a modest reduction below values seen in the DM rats receiving only insulin. Frequent interim blood pressure measurements were performed to ensure continuing blood pressure control; occasionally doses were adjusted in individual rats to maintain the desired blood pressure. Extensive pilot testing established that doses exceeding these levels resulted in excessive hypotension (systolic blood pressure < 100 mm Hg), while doses less than those reported resulted in inadequate blood pressure lowering (systolic blood pressure > 130 mm Hg).
Subsets of rats in each group underwent whole kidney and glomerular hemodynamic studies at four to eight weeks after STZ injection. The long-term groups were followed with bimonthly determinations of systolic blood pressure (SBP) by the tail cuff method, and of 24-hour urinary albumin excretion rates (UalbV) . At eight months, the rats were sacrificed for examination of renal morphology.
Micropuncture studies Following confirmation of desired BG levels, rats were anesthetized with mactin (100 mg/kg i.p.) and placed on a temperature-regulated table. The left femoral artery was catheterized, and a baseline collection of blood was obtained for measurement of hematoci-it (Hct) and inulin "blank". This arterial catheter was used for subsequent periodic blood sampling and estimation of mean arterial pressure (AP) via an electronic transducer connected to a direct-writing recorder. After tracheostomy, venous catheters were inserted for infusions of inulin and plasma. Intravenous infusions of rat plasma, and 10% inulin solution in 0.9% NaCI, were started at rates of 6.0 and 1.2 ml/hr, respectively. The left ureter was catheterized for urine collection, and the left kidney exposed and suspended on a lucite holder, with its surface illuminated and bathed with isotonic saline.
Since the plasma volume of rats prepared for micropuncture is reduced by -20% [11] , euvolemia was maintained using the following protocol. Isoncotic rat plasma was infused at 6 mI/hr in a total amount equal to 1% of the body weight, followed by a reduction in infusion rate to 1.6 ml/kg/hr, to maintain the Hct constant. These diabetic rats received extra saline to match the excessive urinary losses during the procedure, if initial urine flow rates proved excessive.
For calculation of SNGFR, exactly timed samples of tubule fluid were collected for determination of flow rate and inulin concentration. Samples of efferent arteriolar blood were obtained for determination of protein concentration. Coincident with these collections, arterial blood was obtained for determination of Hct and plasma concentrations of inulin and protein, and 10 to 20 minute urine collections were obtained for determination of flow rate and inulin concentration. These measurements permitted calculation of glomerular filtration rate (GFR) These estimates of pre-and post-glomerular plasma protein concentration permit calculation of SN filtration fraction, gbmerular capillary ultrafiltration coefficient (Kr), and afferent and efferent arteriolar blood flow rates and resistances, using equations previously described [12] . At the end of the procedure, blood was obtained for determination of glycosylated hemoglobin (HbA1), after which the kidneys were perfusion-fixed for morphologic studies.
Morphology
Kidneys were perfused at the measured systolic arterial pressure for two to three minutes with 1.25% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4). After perfusion fixation, kidney weights were recorded, and two midcoronal slices of 2 to 3 mm thickness were processed for light microscopic examination. Three-micrometer-thick paraffin sections were stained with hematoxylin and eosin and by the periodic acid Schiff (PAS) reaction. The extent of glomerular damage was determined on PAS-stained slides by counting on two coronal sections all glomerular profiles with segmental or global collapse of capillaries, with or without associated hyalin deposition and adhesion of the tuft to Bowman's capsule. The extent of glomerular sclerosis was expressed as the percentage of glomeruli with sclerotic lesions.
-
The average glomerular tuft volume (VG) for each animal was determined by the procedure described by Weibel [13] . For this purpose, the mean glomerular random cross-sectional area (AG) was determined on 50 systematically sampled glomerular tuft profiles by point counting at a final magnification of 200x using a 361-point ocular grid covering a 369,664 m2 microscopic field. V0 was then calculated as V0 = (/3/sc)(A0)312, where p = 1.38 and ic 1.1 are shape and size distribution coefficients, respectively [13, 14] .
Analytical
The volume of fluid collected from individual proximal tubules was estimated from the length of the fluid column in a constant bore capillary tube of known internal diameter. The tubule fluid inulin concentration was measured by a microfbuorescence method [15] . Inulin concentrations in plasma and urine were measured using a macro-anthrone method [16] . Protein concentrations were determined using a fluorometric method [17] . Urinary albumin concentration was measured by radial immunodiffusion [18] . By this method, the assay is sensitive to a level of 1.25 jig/mI, with a standard deviation of less than 2% of the mean [IS] . Glycosylated hemoglobin was determined by affinity column chromatography (Glyco-Gel B, Pierce Chemical Co., Rockford, Illinois, USA) [19] . Statistical Statistical analysis was performed by one-way analysis of variance followed by computation of modified t values for three preplanned pairwise comparisons according to the method of Bonferroni [20] . Statistical significance was defined as P < 0.05. All values represent means 5EM.
Results

General
Serial values for body weight, SBP, and BG are depicted in Figures 1 to 3 . There were no differences among the groups in body growth (Fig. 1) . Comparable hyperglycemia was maintained in all groups (Fig. 2) . Values for awake systolic blood pressure were modestly and equivalently reduced by FOS and NIP as compared to DM rats, but did not differ between DM/FOS and DM/NIF groups (Fig. 2) . Studies in an additional group of rats (N = 6) receiving the vehicle for nifedipine (that is, placebo injections) did not differ from those in DM rats, confirming that the vehicle did not influence SBP. Pilot studies DM/NIF, 40 6 mi/day) were also above the normal range, but did not differ among the groups.
Time, months of diabetes Systemic and renal hemodynamic parameters Mean values for systemic and whole kidney parameters in rats subjected to micropuncture study are summarized in Table  I . Body weight was similar on average in all groups. Average values for left kidney weight and mean glomerular volume were above the normal range [3, 4] in all groups, but did not differ among the groups. Comparable hyperglycemia, reflected by both blood glucose and HbAIC levels, was evident in all groups. Systemic Hct did not differ among groups. Average values for GFR were above the normal range in all groups, but did not differ from one group to another.
Values for AP, single nephron GFR, and glomerular and tubule microcirculatory parameters at four to eight weeks of diabetes are summarized in Table 2 . Values for AP were normal in DM rats, whereas AP was significantly and comparably reduced in rats receiving FOS or NIF. As in previous studies in diabetic rats [3, 41 , the moderately hyperglycemic diabetic rats exhibited single nephron hyperfiltration, due to elevations in [211, suggesting that the hemodynamic changes were due, in large part, to the diabetic state. Despite the reduction in renal perfusion pressure, neither antihypertensive regimen significantly affected average SNGFR or QA values. However, there were prominent differences in the effects of these regimens on P0. As in previous studies of CEI in diabetic rats [3, 4] , fosinopril effectively controlled glomerular capillary hypertension. Glomerular pressure was lowered by the reduction in perfusion pressure, but also by a significant reduction in RE, efferent arteriolar resistance. In contrast, despite equivalent AP reduction, rats receiving nifedipine exhibited average values for which remained at the same high levels seen in diabetic rats receiving no antihypertensive therapy. Values for P, the glomerular transcapillary hydraulic pressure difference, were also higher in DM/NIF rats, despite a slight increase in average values for proximal tubule pressure, than in DM/FOS rats. Values for the glomerular capillary ultrafiltration coefficient, Kf, were significantly elevated in DMIFOS rats as compared to DM rats, with lesser and insignificant increases in Kf seen in DM/NIF rats. There were no significant differences in arteriolar protein concentrations or colloid osmotic pressures among the groups. Thus, neither antihypertensive drug significantly influenced the single nephron hyperfiltration and hyperperfusion of diabetes, whereas fosinopril, but not nifedipine, normalized glomerular capillary pressure, and increased Kf.
Long-term studies Serial studies confirmed maintenance of equivalent hyperglycemia in all groups, and comparable blood pressure reduction in the groups receiving antihypertensive therapy (Fig. 2) . Final determinations of systemic and renal parameters at eight months of diabetes are summarized in Table 3 . Systolic blood pressures remained equivalently reduced in the treated groups.
As in the studies performed early in diabetes, all groups exhibited values for left kidney weight and glomerular volume Serial values for UV are depicted in Figure 3 , and final values in Table 3 . Diabetic rats receiving only insulin exhibited significant elevations in UalbV as early as one month after induction of diabetes, and UalbV increased markedly over time. Fosinopril therapy very effectively limited the development of UaIbV.
In contrast to the protective effect of CEI, however, rats receiving nifedipine exhibited elevated values for UaIbV early in the course, and marked escalation over time, so that values at the end of the study were as high as those in DM rats not receiving antihypertensive therapy.
Structural changes
The extent of focal and segmental glomerular sclerosis (Table  3 , Fig. 4 ) generally correlated with patterns of albuminuria. The diabetic state was associated with marked glomerular injury, with sclerosis involving 19. 8 2.9% of glomeruli. As in previous studies using CEI therapy in diabetic rats [3, 4] , sclerosis was markedly lessened in DM/FOS rats, averaging only 5.3 1.4% of glomeruli. In contrast, morphologic assessment in DM/NIF rats indicated absence of protection, with values for glomerular sclerosis (16.3 2.3%) being similar to those seen in the DM rats not receiving antihypertensive therapy. Thus, converting enzyme inhibition offered protection against development of glomerular injury, while calcium channel blockade was ineffective.
Discussion
Both antihypertensive regimens employed in this study effectively lowered systemic blood pressure, thereby enabling comparison of the effects of these different classes of antihypertensive therapy. Despite comparable effects on systemic blood pressure, and absence of any difference in metabolic control, the long-term sequelae of these therapeutic regimens differed substantially. In accord with many previous studies of CEI therapy in diabetic [3-51 and other [22-24] experimental models, converting enzyme inhibition with fosinopril very effectively reduced albuminuria at every determination, and significantly limited the development of glomerular sclerosis. Of note, however, were the findings with the calcium antagonist nifedipine, which afforded no protection against the development of albuminuria or glomerular injury. Calcium antagonists are widely used in the treatment of hypertension, because of their effective hypotensive potency and relative absence of troubling metabolic side effects. However, studies using this class of agents to examine progression of experimental renal disease have yielded conflicting results. In the remnant kidney model, it has been reported that verapamil in non-hypotensive doses affords protection [25] , while others have found hypotensive doses ineffective [26] . Nifedipine and other dihydropyridine derivatives have been more successful in preventing glomerular injury in rats with systemic hypertension and progressive renal disease [24, [28] [29] [30] , though not without exception [27, 31] . Of the third clinically-available class of calcium antagonists, diltiazem and its derivatives have also proven variable with respect to renal protection [32] [33] [34] . Our results further reinforce the conclusion that dihydropyridine calcium antagonists may offer inconsistent protective ability, in this case failing to protect in the setting of experimental diabetes. It seems likely that failure to control glomerular capillary hypertension explains the absence of structural protection afforded by nifedipine. Numerous previous studies in diabetic [3, 4] and other [22, 23] experimental models have confirmed the association between reduction of glomerular pressure, and amelioration of glomerular injury; antihypertensive regimens which fail to afford continuing control of glomerular hypertension have frequently not been successful [4, 22] , For example, previous studies in diabetic rats indicated that the combination of reserpine, hydralazine and hydrochlorothiazide lowered P6 and UalbV early in the course, but failed to provide sustained reduction in either parameter, and thus was less effective than captopril in reducing injury [4] . Fosinopril, like other converting enzyme inhibitors [3, 4] , effectively lowered P0 by reducing both AP and R. The reduction in efferent arteriolar resistance, in turn, is most likely due to interference with the action of angiotensin lion this vascular segment; indeed, recent studies using a specific angiotensin II receptor antagonist have found similar hemodynarnic effects in diabetic rats [35] . The effects of nifedipine on P0 have proven variable, with this regimen controlling glomerular hypertension in some experimental models [24] but not in others [281. Though it has been postulated that calcium antagonists interfere with the action of angiotensin II, failure of nifedipine to reduce R in this study suggests that such a mechanism is not prominent in efferent arteriolar microvascular regulation in vivo.
it has been reported that reducing blood pressure with nifedipine lessens glornerular sclerosis in mineralocorticoid-salt rats without reducing POC [28] ; however, our findings in experimental diabetes clearly indicate no protective effect of nifedipine in this model. As in our previous studies in diabetic rats [4] , we also found no correlation between renal or glomerular enlargement and development of injury. In the former study, both captopril and combination therapy resulted in similar limitations in glomerular volume, as compared to diabetic rats not receiving antihypertensive therapy [41. In the present study, neither antihypertensive regimen limited structural growth, and thus effects on growth cannot be invoked to explain the differences between CEI and calcium channel blocker therapy in limiting injury. The differences between these studies regarding effects of antihypertensive therapy on glomerular volumes could relate to the differing duration of study, and/or to added hypertrophic influence of uninephrectomy in the present study. Other modulating factors, such as changes in size of specific intraglomerular components, cannot be excluded, though no such differences were qualitatively apparent. Finally, the role of serum cholesterol was not specifically addressed in this study; however, the degree of hyperlipidemia in this model is modest, and neither class of antihypertensive drugs is generally associated with consistent changes in serum lipid levels.
Long-term clinical trials comparing ability of antihypertensive regimens to slow progression of diabetic nephropathy are not yet conclusive. Relatively short-term studies examining the influence of antihypertensive therapy with calcium antagonists on UaIbV in diabetic patients have also provided somewhat conflicting results. Both Demarie and Bakris [9] and Mimran et at [8] found that while CEI significantly reduced UalhV in diabetic patients, equivalent reductions in blood pressure with nifedipine resulted in actual increases in UlbV. This augmentation of UajbV may not be found with all calcium antagonists, given recent reports of reductions in UUIbV with diltiazem [7, 9] and of the ability of verapamil to enhance the antiproteinuric effect of CEI [10] in diabetic patients. Since both diltiazem and verapamil normalize P0 in remnant kidney rats [36] , their antiproteinuric efficacy in diabetic patients could relate to similar salutory hemodynamic effects. In contrast to these findings, other studies in patients with incipient nephropathy and minimal albuminuria [37] , and in patients with type II diabetes [38] , have noted equivalent effects on UlbV in comparison trials of nifedipine and CU therapy. At present, explanations for these disparate findings with nifedipine in diabetic patients are lacking. However, these conflicting reports contrast with the almost uniformly beneficial results of studies using CLI therapy. Converting enzyme inhibitors have been shown to reduce Ua)bV in numerous clinical studies, in patients ranging from early diabetes with normoalbuminuria or microalbuminuria, to those with advanced diabetic nephropathy [39] .
In summary, the long-term consequences of fosinopril and nifedipine were compared in moderately hyperglycemic, uninephrectomized diabetic rats. Blood pressure was modestly and comparably reduced in both treated groups as compared to diabetic rats receiving only insulin. Neither regimen affected the single nephron hyperfiltration or hyperperfusion of diabetes. However, while fosinopril effectively controlled glomerular hypertension, nifedipine did not. Reduction of both systemic and glomerular pressures with fosinopril was associated with striking protection against development of albuminuria and glomerular injury, whereas reducing systemic but not glomerular pressure with nifedipine afforded no renal protection. These findings suggest that differing antihypertensive regimens may not prove equally effective in protecting the diabetic kidney, and that long-term clinical trials comparing various antihypertensive regimens are needed to define optimal therapy of this patient population at high risk for development of advanced nephropathy and end-stage renal disease.
